Th e objective of the present study was to compare antibiotic prescribing practices and survival in the ICU for patients with pneumococcal severe community-acquired pneumonia (SCAP) between 2000 and 2013.
Community-acquired pneumonia (CAP) is a major health problem associated with high morbidity and mortality. 1, 2 Despite geographic diff erences, Streptococcus pneumoniae is the most common cause of pneu monia worldwide. 1 Over the years, CAP studies have focused on risk factors, 3 microbiology, 4 ,5 biomarkers, 6, 7 and mortality 8 ; more recently, they have addressed the introduction of new antibiotic policies and the availability of new drugs. 9, 10 In Western countries, despite improved survival due to changes in antibiotic policies, [11] [12] [13] poor prognosis is seen in older people with more comorbidities and chronic illness in whom life expectancy has been pro longed. [14] [15] [16] [17] On the other hand, it has been shown that septic shock mortality has decreased. [18] [19] [20] Th e aggregate impact of these demographic and clinical trends on the CAP survival rate is of great importance to clinicians, but no recent data are available in the literature, especially in critical patients with severe community-acquired pneumonia (SCAP).
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Our hypothesis was that improvement in antibiotic policies contributed to reduced mortality due to SCAP in the ICU setting. For this reason, the primary objective of the present study was to compare ICU mortality due to SCAP caused by S pneumoniae in two diff erent periods (2000-2002 and 2008-2013) . Th e secondary objective was to identify changes in antibiotic strategies in pneumococcal SCAP.
Results
One hundred and sixty patients were enrolled: 80 patients from the 2008 to 2013 cohort (case group) paired with 80 from the 2000 to 2002 cohort (control group). Figure 1 shows the algorithm for the selection of the patients and the ICU mortality for each subgroup; incidence of severe pneumococcal pneu mo nia increased signifi cantly (43.9% vs 27.0%; OR, 1.30; 95% CI, 1.15-1.48). Table 1 shows the variables used to match patients. Th e groups presented identical prevalence of the items evaluated: Shock at ICU admission was present in 60.0% of patients, while 65.0% had received mechanical ventilation. Th irty-three percent of patients were aged . 65 years, 32.2% received a diagnosis of COPD, and 7.5% presented immunosuppression. The cause of immunosuppression was HIV infection in seven of 12 patients.
Medical history and clinical presentation were comparable in the two cohorts ( Table 2 ) . Estimated probability of death was 31.0% in the case group and 24.0% in the control group ( P 5 .35 ). ICU length of stay was similar: Median (IQR) was 10.0 days (4-19) vs 10.0 days (4-17.8), respectively ( P 5 .97 ). Blood cultures were positive in 36.2% of the case group and 40.0% of the
Materials and Methods
Th is was a matched case-control study of two cohorts of patients prospectively recorded in Europe (the Community-Acquired Pneu monia en la Unidad de Cuidados Intensivos [CAPUCI] studies). CAPUCI I and II are two European, prospective, multicenter stud ies conducted in patients admitted to the ICU for CAP. Th e CAPUCI I study recorded data from 33 hospitals from 2000 to 2002. Data from this cohort have been reported elsewhere. 11 Th e CAPUCI II study was a follow-up project endorsed by the European Critical Care Research Network. Data were recorded from patients admitted for SCAP from 2008 to 2013 in 29 European ICUs. Demographic data, and clinical presentation, outcome, and antibiotic therapy data were registered; antibiotic prescription was left to the discretion of the attending physician. Patients were admitted to the ICU either to undergo mechanical ventilation or because they were critically ill, 21 in accordance to Infectious Dis ease Society of America/American Th oracic Society guidelines. 1 People with severe chronic illness in whom pneumonia was an expected terminal event were not included; patients were observed until ICU discharge or death. Th e study was approved by the ethics board of the coordinating center (REF 2005/NA), in accordance with national regulations, and informed consent was waived due to the observational nature of the studies. Defi nitions are given in e-Appendix 2.
Eighty patients (case group, n 5 80) from the CAPUCI II database who were diagnosed with SCAP caused by S pneumoniae were matched with 80 patients with similar clinical characteristics from the CAPUCI I database (control group, n 5 80). For each patient in the case group, one patient with identical clinical features was selected from the control group. Matching variables were the following: presence of shock at ICU admission, need for mechanical ventilation, immunosuppression, and age (age cutoff : 65 years), 22 as these are the main determinants for mortality in CAP, 23, 24 and COPD, given its high prevalence in Western populations and its controversial role in the increase in mortality in SCAP. 25, 26 Continuous variables were compared with Student t test for normally distributed variables, or the Mann-Whitney U test for nonnormally distributed variables. Categorical variables were evaluated with the x 2 or two-tailed Fisher exact test. Results are expressed as median and interquartile range (IQR) for continuous variables or as percentages of the group from which they were derived for categorical variables. Two-tailed tests were used to determine statistical signifi cance; a P value , .05 was considered signifi cant.
Th e Kaplan-Meier product limit method was used to construct survival curves for patients receiving combination and monotherapy regimens and early vs late antibiotic administration. All data management and statistical analysis were performed using the SPSS 15 processor (IBM). control group ( P 5 .75). As shown in Table 3 , bacteremia was signifi cantly associated with the presence of septic shock ( P 5 .05). Acute kidney injury was observed in 44 patients (55.0%) in the case group vs 31 (39.2%) in the control group ( P 5 .06), while rapid radiographic spread was recorded in 48.8% and 51.2%, respectively ( P 5 .87).
ICU mortality was signifi cantly diff erent between the groups: 14 patients (17.5%) from the case group died compared with 27 (32.5%) in the control group, with an OR of ICU mortality of 0.82 (95% CI, 0.68-0.98; P 5 .04). Most deaths were late and due to multiorgan dysfunction syndrome. Figure 1 shows ICU mortality of the diff erent subgroups. Mortality was comparable between matched and nonmatched patients in CAPUCI I (22.6% vs 33.8%, P 5 .26) and in CAPUCI II (17.5% vs 14.3%, P 5 1.00). Figure 2 shows changes in ICU mortality between the two time periods in the whole population and in the subgroups of patients with shock (OR, 0.67; 95% CI, 0.50-0.89) and those receiving mechanical ventilation (OR, 0.73; 95% CI, 0.55-0.96). Kaplan-Meier survival analysis was performed in the global cohort and in the subgroups of patients with shock and under mechanical ventilation , stratifying by monotherapy vs combined therapy (log-rank P , .01, .02, and .01, respectively) ( Fig 3) and early vs non-early antibiotic treatment (log-rank P , .01, .01, and .02, respectively) ( Fig 4) .
Combined therapy diff ered signifi cantly between the groups: 70 patients (87.5%) from the case group received combined therapy vs 53 (66.2%) from the control group ( P , .01) ( Table 6 shows the univariate analysis for determin ing variables associated with ICU mortality. COPD ( P 5 .05), estimated probability of death ( P , .01), shock at ICU admission ( P , .01), invasive mechanical ventilation ( P , .01), acute kidney injury ( P 5 .02), rapid radiographic spread ( P 5 .02), combined therapy ( P 5 .02), and early antibiotic administration ( P 5 .02) diff ered signifi cantly between survivors and nonsurvivors.
Multivariate analysis was performed to identify risk factors for mortality ( Table 7 ) . Variables with significant diff erences from the univariate model ( Table 6 ) were introduced in this model. 
Discussion
Th e main fi nding of this study was a 15% decrease in ICU mortality due to SCAP caused by S pneumoniae during the study period. Several changes in antibiotic prescription practices were detected, and an association between improved survival and both earlier antibiotic administration and increased combined antibiotic therapy was identifi ed.
Th e World Health Organization's annual reports stress the minimal decrease in worldwide mortality secondary to lower respiratory infection: from 4.1 million (1993) to 3.9 million (2002). 27, 28 Mortality due to all-source infectious diseases has increased in recent decades, 29 up to 58% in the United States. 30 However, its translation to clinical practice is diffi cult because no diff erentiation has been made between mild and severe infection, or local infection, sepsis or septic shock, considering that complicated infection with systemic infl ammatory response syndrome bears higher mortality than local infection. 31 In accordance with our results, there is evidence supporting a decrease in severe sepsis and septic shock mortality in the last years 32 : Overall mortality from anysource severe sepsis had decreased in the last decade up to 12%. 19, 20 Explanations for this trend include higher compliance with international guidelines, 33, 34 better hemodynamic management, 35 improved ventilator setting in mechanical ventilation, 36, 37 decreased ICU admissions of patients with extremely poor prog nosis, 19 and changes in medical treatment. 35, [38] [39] [40] Studies showing that early antibiotic administration seems to be unrelated to better outcomes did not diff erentiate between critical and noncritical patients. 41, 42 It has consistently been demonstrated that early antibiotic administration is a determinant of the outcome in severe sepsis and shock, regardless the source of infection, [38] [39] [40] supporting the 2012 Surviving Sepsis Campaign's recommendation on initiation of antibiotics within the fi rst hour of the diagnosis of severe sepsis. 35 Our results show that combined antibiotic therapy is associated with lower ICU mortality, which is supported by other studies [43] [44] [45] [46] ; however, most of these enrolled patients with pneumonia and shock. Our data show improved survival in patients receiving combined therapy, both in the general population and in patients with shock or receiving mechanical ventilation ( Fig 3 ) , suggesting that the benefi t of combined therapy is not limited to patients with shock.
Still, it is unclear why combined therapy is superior to monotherapy. Possible reasons include coverage of atypical pathogens, greater probability of covering Table 3 for expansion of other abbreviation.
[ 1 4 6 # 1 C H E S T J U LY 2 0 1 4 ] multiresistant microorganisms, synergies, and antiinfl ammatory and immunomodulatory eff ects of some antimicrobials. In the present study, as all cases were caused by S pneumoniae , it is reasonable to assume that factors other than covering atypical pathogens or covering multiresistant microorganisms were related to decreased mortality.
Interestingly, epidemiology of invasive pneumococcal disease changed significantly in Spain after the introduction of the 7-valent pneumococcal conjugate vaccine , where a shift in pneumococcal serotypes has been documented (serotypes not covered by the vaccine). This has been associated with more empyema and different rates of shock or respiratory failure. [47] [48] [49] Substantial reduction in hospitalization for pneumonia among adults has been reported after introduction of the 7-valent pneumococcal conjugate vaccine. 50 See Table 3 and 6 legends for expansion of abbreviations.
A signifi cant decrease in mortality was observed in the whole population as well as in the subgroups of patients with shock and receiving mechanical ventilation ( Fig 2 ) , even when stratifi ed according to combined antibiotic therapy vs monotherapy ( Fig 3 ) and early antibiotic treatment vs non-early antibiotic administration ( Fig 4 ) . Th is observation is not only of academic interest: In view of these results, all patients with pneu mococcal SCAP requiring ICU admission should receive early treatment and combined antibiotic therapy.
Significant differences in antibiotic regimens administered to the study groups were seen ( Table 5 ) , the most important being that azithromycin was not administered to the control group, because it was not available in IV formulation in Spain at the time of the CAPUCI I study. Also, more broad-spectrum antibiotic combinations were administered in the control group than in the case group; in the case group, 80.0% of patients received a combination of cephalosporin plus a macrolide or fluoroquinolone compared with 47.6% of control subjects, suggesting a higher compliance to guidelines in the case group. No differences in mortal ity were found between different antibiotic regimens.
Interestingly, our study population comes from a large, prospective, multicenter database and is homogeneous, since all the patients were admitted to the ICU. To our knowledge, this is the fi rst study to compare the clinical characteristics of the subset of critically ill patients in the ICU with pneumococcal CAP. Moreover, whereas most prior studies evaluating antibiotic treatment in SCAP have been limited to subgroups with shock, our results showed a lower mortality rate in different populations, stressing the clinical implications of our fi ndings.
Th e major limitation of the present study is its design, where prescription of antibiotics and hemodynamic resuscitation were not standardized. On the other hand, there were no signifi cant diff erences between the two cohorts ( Tables 1, 2 ) .
Another important limitation is that several improvements have been introduced in the management of critical patients, including management of septic shock and mechanical ventilation. Even though major determinants of mortality for SCAP were included in our analysis, it was not possible to record all of these changes. Severity of illness was recorded with diff erent scores; therefore, univariate and multivariate analysis adjusted severity for the "estimated risk of death" rather than a score. We acknowledge that the use of matching criteria for respiratory failure other than mechanical ventilation, such as Pa o 2 /F io 2 , may be associated with diff erent outcomes, but this may also be infl uenced by other supporting measures like positive end-expiratory pressure level or other ventilator settings. Bacteremia alone is not a good tool to predict outcome in pneumococcal pneumonia 51 ; for this reason, this variable was not used to match cohorts. Although reports [47] [48] [49] have correlated variation in serotypes with outcomes and complications, data regard ing vaccination or serotypes were not recorded in our study. Finally, a selection bias may limit the generalization of fi ndings.
Conclusions
In summary, incidence, mortality, and management of severe pneumococcal pneumonia has signifi cantly changed in the last decade. Improved ICU survival was associated with earlier antibiotic prescription and increased use of combined antibiotic therapy.
